Alcobra Announces Shares Uplisted to NASDAQ Global Market
March 26, 2014 08:00 ET
|
Alcobra Ltd.
TEL AVIV, Israel, March 26, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary...
Alcobra Announces Enrollment of First Patient in Phase 3 Clinical Trial for MDX in Adult ADHD
March 18, 2014 08:00 ET
|
Alcobra Ltd.
TEL AVIV, Israel, March 18, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary...
Alcobra Announces FDA Clearance of IND for Metadoxine Extended Release (MDX)
March 06, 2014 09:15 ET
|
Alcobra Ltd.
TEL AVIV, Israel, March 6, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug...
Alcobra Ltd. to Discuss Biomarkers in Fragile X and Autism Trials at the Second Annual Autism Investment Conference
February 24, 2014 08:00 ET
|
Alcobra Ltd.
TEL AVIV, Israel, Feb. 24, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug...
Alcobra Appoints J.P. Morgan Banker Dr. Tomer Berkovitz as Chief Financial Officer
February 19, 2014 08:00 ET
|
Alcobra Ltd.
TEL AVIV, Israel, Feb. 19, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug...
Alcobra Announces Fourth Quarter and Fiscal Year End 2013 Financial Results and Corporate Update
February 13, 2014 08:00 ET
|
Alcobra Ltd.
TEL AVIV, Israel, Feb. 13, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug...
Alcobra Announces IND Submission for Extended Release Metadoxine to Treat Adults With ADHD
February 07, 2014 13:58 ET
|
Alcobra Ltd.
TEL AVIV, Israel, Feb. 7, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug...
Alcobra Ltd. to Provide Corporate Overview at 16th Annual BIO CEO & Investor Conference
January 31, 2014 08:00 ET
|
Alcobra Ltd.
TEL AVIV, Israel, Jan. 31, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug...
Alcobra Ltd. to Release Fourth Quarter 2013 Results and Host Investor Conference Call on Thursday, February 13, 2014
January 29, 2014 08:00 ET
|
Alcobra Ltd.
TEL AVIV, Israel, Jan. 29, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug...
Alcobra Announces New Biomarker Finding in a Follow-Up Fragile X Animal Study for MG01CI
January 27, 2014 08:00 ET
|
Alcobra Ltd.
- Improved Cognitive Function and Social Interaction Correlated With Changes in Blood Levels of Fragile X-Specific Molecular Targets
- Clinical Study With MG01CI in Fragile X Syndrome...